Life science investment firm Ally Bridge Group (ABG) has led three US medtech investments amid the Covid-19 pandemic.
Each of the three companies could have a role to play as the pandemic continues.
Go deeper with GlobalData
ABG has led a $25m investment in Vida Health, an all-in-one virtual care platform managing polychronic physical and behavioural conditions such as diabetes, obesity, hypertension and mental health conditions.
The investment group has also led a $60m investment in Rapid Micro Biosystems, a life science tools company that offers products for the detection and data-tracking of bacterial contamination in the manufacturing of pharmaceuticals, biologics, medical devices, water and food processing, and personal care products.
Finally, it has led an investment of a further $66m in Pulmonx, a medical device company specialising in minimally invasive treatment for patients with severe emphysema.
ABG founder and CEO Frank Yu said: “The Covid-19 pandemic is undoubtedly a watershed event for life science and healthcare around the globe, and further strengthens ABG’s commitment to leading high-impact investments in game-changing innovations in this space.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
